Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

BACKGROUND: To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA) METHODS: Patients who completed the 2-year, open-label, phase III CLinical Stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Foeldvari, Ivan, Constantin, Tamàs, Vojinović, Jelena, Horneff, Gerd, Chasnyk, Vyacheslav, Dehoorne, Joke, Panaviene, Violeta, Sušić, Gordana, Stanevicha, Valda, Kobusinska, Katarzyna, Zuber, Zbigniew, Dobrzyniecka, Bogna, Nikishina, Irina, Bader-Meunier, Brigitte, Breda, Luciana, Doležalová, Pavla, Job-Deslandre, Chantal, Rumba-Rozenfelde, Ingrida, Wulffraat, Nico, Pedersen, Ronald D., Bukowski, Jack F., Vlahos, Bonnie, Martini, Alberto, Ruperto, Nicolino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533709/
https://www.ncbi.nlm.nih.gov/pubmed/31122296
http://dx.doi.org/10.1186/s13075-019-1916-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533709/
https://www.ncbi.nlm.nih.gov/pubmed/31122296
http://dx.doi.org/10.1186/s13075-019-1916-9

Ejemplares similares